New Delhi: A new Coronavirus variant, PJ.2.1, is currently making headlines globally as it spreads across several countries, including the US, Europe, Australia, and parts of Asia. First identified in Ontario, Canada, on May 2, 2026, the variant has since been reported in nations like Singapore, Israel, France, Spain, and New Zealand. As the virus continues to evolve, health experts are closely monitoring its transmission and potential impact.
A study published in the ‘Journal of Infection’ in October 2026 revealed that PJ.2.1 is closely related to MC.10.1.7, an older variant of the JN.1 lineage. Scientists describe it as a “saltation variant,” meaning it has undergone a significant number of genetic mutations all at once rather than gradually. Researchers found that the spike protein of PJ.2.1 binds more effectively to the ACE2 receptor, the entry point for the virus into human cells, potentially making it highly transmissible.
Despite its rapid spread, there is currently no clinical evidence suggesting that PJ.2.1 causes more severe illness or leads to higher hospitalization and mortality rates compared to previous strains. Furthermore, initial lab studies indicate that antibodies from prior vaccinations can still recognize and neutralize the variant, suggesting that existing immunity is not entirely compromised.
The symptoms of PJ.2.1 are largely similar to general Covid-19 and flu infections. Patients have reported fever, chills, severe sore throat, cough, runny or blocked nose, headache, body aches, and fatigue. The World Health Organization (WHO) notes that because Covid and influenza symptoms often overlap, clinical testing is the only definitive way to identify the infection.
Health professionals are advising vulnerable groups, including the elderly and those with compromised immunity or chronic illnesses like diabetes and heart disease, to take extra precautions. Wearing masks in crowded places, maintaining hand hygiene, and ensuring good indoor ventilation remain effective preventive measures.
While the global spread has raised concerns, there is no official confirmation regarding the widespread presence of PJ.2.1 in India yet. It was also absent from the WHO’s variant monitoring list as of July 2026. Therefore, experts emphasize the need for scientific monitoring and general caution rather than panic.